SynthesisBMC pregnancy and childbirth2025
Global prevalence and risk of gastroesophageal reflux disease symptoms in pregnancy: a systematic review and meta-analysis.
Synthesis in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mitral Valve Prolapse and Anxiety Disorders: A Systematic Review of Evidence in Both Directions and Meta-Analysis.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastroesophageal reflux disease (GERD), manifested by heartburn and regurgitation, is a common pregnancy complaint that significantly impairs quality of life. Reported prevalence varies widely, with differences observed across pregnancy trimesters. This first systematic review and meta-analysis synthesizing global data aimed to estimate the pooled prevalence and risk of GERD symptoms during pregnancy, including trimester-specific trends. METHODOLOGY: Following PRISMA 2020 guidelines, a comprehensive literature search was conducted across MEDLINE/PubMed, EMBASE, Cochrane Library, and Google Scholar from 1 January 1975 to 10 July 2025. The protocol was registered in PROSPERO (CRD420251102794). Eligible studies included observational studies reporting the prevalence of GERD symptoms in pregnant populations. Two independent reviewers screened articles, extracted data, and assessed methodological quality using the Newcastle-Ottawa Scale. A random-effects meta-analysis model was applied.
resultsA total of 21 studies involving 9497 pregnant participants were included. The pooled prevalence of GERD symptoms during pregnancy was 40.96% (95% CI: 27.63-54.28). Subgroup analysis by trimester revealed a progressive increase in GERD prevalence, from 26.12% in the first trimester to 33.40% in the second, peaking at 55.93% in the third, reflecting the growing physiological burden. In studies that included non-pregnant control groups, pregnant women had a significantly higher risk of experiencing GERD symptoms compared to non-pregnant controls (OR = 8.37; 95% CI: 2.93-23.89). Subgroup analysis showed that the pooled prevalence of heartburn was 43.81% (95% CI: 23.74-63.87), while regurgitation affected 37.94% (95% CI: 26.23-49.65) of pregnant women.
conclusionGERD symptoms are highly prevalent during pregnancy, especially in the third trimester. Early identification and management may improve maternal comfort and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.